Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 51 CME4 | DOI: 10.1530/endoabs.51.CME4

Newcastle.


Key discussion points

• Make sure you know what it is that you are treating – is this Graves’ hyperthyroidism (with associated TSH receptor antibodies) or simply a brief, hyperthyroid phase of autoimmune thyroid disease (without TSH receptor antibodies) that will settle down spontaneously?

• Ideally obtain the result of the thyroid receptor antibody titre pre intervention with carbimazole.

• Unrecognised Graves’ can have a profound impact on educational attainment. Time with unrecognised Graves’ can compromise an individual’s ability to learn to a major degree.

• All treatment modalities – carbimazole, radioiodine (RI) and surgery – have their advantages and disadvantages. Tailoring therapy to the individual according to factors such as age, goitre size and future plans is important.

• ‘Block and replace’ antithyroid drug therapy may be appropriate in some instances despite the increased likelihood of adverse events.

• Some patients with Graves’ will not only remit but will also become hypothyroid.

• Life on long-term thyroid hormone replacement post-surgery or post-RI is not perfect – we need new treatments for Graves’ hyperthyroidism that increase the likelihood of long-term remission.

Volume 51

45th Meeting of the British Society for Paediatric Endocrinology and Diabetes

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts